Liu Jieqiong, Deng Heran, Jia Weijuan, Zeng Yunjie, Rao Nanyan, Li Shunrong, Jin Liang, Wu Jiannan, Song Erwei, Su Fengxi
Department of Breast Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
J Cancer Res Clin Oncol. 2012 May;138(5):837-42. doi: 10.1007/s00432-012-1150-1.
The aim of this study was to determine whether estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) statuses between primary tumors and paired liver metastatic localizations of breast carcinoma were modified by treatment or during the natural metastatic process.
ER, PR, and HER2 expressions were analyzed on paired tissue specimens taken from the primary and the liver metastatic tumors in breast cancer patients. The first group included 46 women who presented with T1-T4, N0-N3, M0 breast carcinoma when first diagnosed and were treated by neoadjuvant therapy or directly underwent surgery, then received postoperative treatment and developed liver metastasis several months/years later. The second group included 12 patients with liver metastatic breast carcinoma when first diagnosed for breast cancer. HER2 status was determined by immunohistochemistry as well as fluorescence in situ hybridization.
Among the 46 patients in the first group, the ER/PR and HER2 statuses (when considered as a whole histological subtype) were changed between primary tumor and liver metastatic lesions in 12 patients (26.1%). While ER and PR status were modified in 14 (30.4%) and 25 (54.3%) patients, respectively, there were only 5 (10.9%) cases showed a discrepancy in the HER2 status. In the second group, the ER/PR and HER2 statuses (when considered as a whole subtype) were consistent between primary and liver metastatic tumor in 10 of 12 (83.3%) patients. ER, PR, and HER2 statuses were modified in 0 of 12 (0%), 4 of 12 (33.3%), and 1 of 12 (8.3%) cases, respectively.
ER/PR and HER2 statuses between primary and liver metastatic lesions of breast carcinoma can be modified after treatment but are stable in most cases during the natural metastatic process.
本研究旨在确定乳腺癌原发肿瘤与配对的肝脏转移灶之间的雌激素受体（ER）/孕激素受体（PR）和人表皮生长因子受体2（HER2）状态在治疗过程中或自然转移过程中是否发生改变。
对乳腺癌患者原发肿瘤和肝脏转移瘤的配对组织标本进行ER、PR和HER2表达分析。第一组包括46名女性，她们首次诊断时为T1-T4、N0-N3、M0期乳腺癌，接受新辅助治疗或直接手术，术后接受治疗，数月/数年后发生肝脏转移。第二组包括12名首次诊断为乳腺癌时即有肝脏转移的患者。HER2状态通过免疫组织化学以及荧光原位杂交确定。
第一组的46例患者中，12例（26.1%）原发肿瘤与肝脏转移灶之间的ER/PR和HER2状态（视为整个组织学亚型）发生了改变。ER和PR状态分别在14例（30.4%）和25例（54.3%）患者中发生改变，而HER2状态仅在5例（10.9%）患者中出现差异。第二组中，12例患者中有10例（83.3%）原发肿瘤与肝脏转移瘤之间的ER/PR和HER2状态（视为整个亚型）一致。ER、PR和HER_{2}状态分别在12例中的0例（0%）、4例（33.3%）和1例（8.3%）患者中发生改变。
乳腺癌原发灶与肝脏转移灶之间的ER/PR和HER2状态在治疗后可能发生改变，但在自然转移过程中的大多数情况下是稳定的。
